Ultragenyx Pharmaceutical Inc at Barclays Virtual Gene Editing & Therapy Summit Transcript
Good morning, everyone. My name is Gena Wang, and I'm (inaudible) analyst at the Barclays. Welcome to our seventh Gene Editing Gene Therapy Summit Conference. I would like to thank all the participants, investors, companies and especially our event team and corporate access team who made this event possible. With that, I would like to introduce our next presenters, Eric Crombez, Chief Medical Officer, Gene Therapy from Ultragenyx.
Eric, thank you very much for joining us today.
Right. Great to be here.
Questions & Answers
Yes. So I know last week, we just had the ASGCT, you present quite some update last week. So maybe I would just start with a question on your several gene therapy programs. First one is the DTX401 and GSDIa, so when we look at the ASGCT update a longer
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |